Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.42 |
| ▸ | HTR1A | P08908 | 7/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395230 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| SCHEMBL22009777 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| SCHEMBL22697071 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| SCHEMBL31159684 | 1.00 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| Sulfuric Acid SCHEMBL29556047 | 0.94 | HTR6 (0.41) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| Trifluoroacetic Acid SCHEMBL30118460 | 0.91 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| SCHEMBL29556433 | 0.84 | HTR6 (0.40) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| SCHEMBL22009927 | 0.84 | HTR6 (0.40) | SLC6A2SLC6A4SLC6A3HTR1AKCNH2 | |
| SCHEMBL24186719 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 | |
| SCHEMBL24320323 | 0.83 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3HTR1ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3806955-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3806955-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219487-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219487-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3806955-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-112533674-A | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2021-03-19 | — | — | CN | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2020234726-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | SLC6A2 1928/4885SLC6A4 978/4885SLC6A3 1006/4885 |
| US-10676465-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | SLC6A2 2680/4885SLC6A4 1445/4885SLC6A3 1820/4885 |
| US-20210163455-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | SLC6A2 2680/4885SLC6A4 1445/4885SLC6A3 1820/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | SLC6A2 2680/4885SLC6A4 1445/4885SLC6A3 1820/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | SLC6A2 334/4885SLC6A4 238/4885SLC6A3 246/4885 |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | SLC6A2 2680/4885SLC6A4 1445/4885SLC6A3 1820/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | SLC6A2 1928/4885SLC6A4 978/4885SLC6A3 1006/4885 |
| US-10934279-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | SLC6A2 2680/4885SLC6A4 1445/4885SLC6A3 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.